All In Biotech

Drug Trial Radar · NCT07565597

A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.

A Single-dose, Randomized, Open-label, Four-period, Replicate Crossover, Comparative Pharmacokinetic Study of Two Formulations of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants Under Fasting Conditions.

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

64

Actual

Start

May 12, 2026

Primary completion

Feb 2027

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will compare the pharmacokinetics (PK) effect of two different formulations of Gecacitinib Hydrochloride Tablets in healthy Adult participants

Conditions

  • Healthy

Interventions

  • Gecacitinib Hydrochloride TabletsDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) Of Gecacitinib and its main metabolite ZG0244Time frame: up to 48 hours
  2. Gecacitinib and its main metabolite ZG0244 AUC(0-t)Time frame: up to 48 hours
  3. Gecacitinib and its main metabolite ZG0244 AUC(0-inf)Time frame: up to 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Hospital of Changsha

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.